Kezar Life Sciences Inc KZR:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 11/25/22 EST
7.46UNCH (UNCH)
Close
7.46quote price arrow down-0.22 (-2.86%)
Volume
173,764
52 week range
4.30 - 18.55
Loading...
  • Open7.61
  • Day High7.62
  • Day Low7.36
  • Prev Close7.68
  • 52 Week High18.55
  • 52 Week High Date03/18/22
  • 52 Week Low4.30
  • 52 Week Low Date06/13/22

Key Stats

  • Market Cap510.10M
  • Shares Out68.38M
  • 10 Day Average Volume0.70M
  • Dividend-
  • Dividend Yield-
  • Beta0.19
  • YTD % Change-55.38

KEY STATS

  • Open7.61
  • Day High7.62
  • Day Low7.36
  • Prev Close7.68
  • 52 Week High18.55
  • 52 Week High Date03/18/22
  • 52 Week Low4.30
  • 52 Week Low Date06/13/22
  • Market Cap510.10M
  • Shares Out68.38M
  • 10 Day Average Volume0.70M
  • Dividend-
  • Dividend Yield-
  • Beta0.19
  • YTD % Change-55.38

RATIOS/PROFITABILITY

  • EPS (TTM)-1.02
  • P/E (TTM)-7.33
  • Fwd P/E (NTM)-6.71
  • EBITDA (TTM)-63.538M
  • ROE (TTM)-31.92%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)3.45%

EVENTS

  • Earnings Date03/15/2023(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Kezar Life Sciences Inc

 

Profile

MORE
Kezar Life Sciences, Inc. is a clinical-stage biopharmaceutical company that is focused on discovering and developing small molecule therapeutics to treat unmet needs in immune-mediated diseases and cancer. The Company's product portfolio includes KZR-616 and KZR-261. The KZR-616 is a selective immunoproteasome inhibitor that has completed Phase Ia testing in healthy volunteers and a Phase Ib trial in patients with systemic lupus erythematosus (SLE). KZR-261 is being studied...
Graham Cooper
Independent Chairman of the Board
John Fowler
Chief Executive Officer, Director
Christopher Kirk Ph.D.
President, Chief Scientific Officer, Director
Marc Belsky
Chief Financial Officer, Secretary
Address
4000 Shoreline Ct Ste 300
South San Francisco, CA
94080-2005
United States

Top Peers

SYMBOLLASTCHG%CHG
ATAI
ATAI Life Sciences NV
3.09-0.08-2.52%
AKUS
Akouos Inc
13.20+0.03+0.23%
DYN
Dyne Therapeutics Inc
10.70+0.20+1.90%
RAPT
Rapt Therapeutics Inc
18.18+0.34+1.91%
GHRS
GH Research PLC
11.92-0.03-0.25%